Beyond Yamanaka: Mogrify demystifies cellular reprogramming

Beyond Yamanaka: Mogrify demystifies cellular reprogramming

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Startup moves into animal studies of direct cellular reprogramming therapies for vision loss, hearing loss, and diabetes.

British cellular reprogramming outfit Mogrify recently boosted its coffers, closing a healthy $46 million Series A funding round, bringing total investment in the company to more than $50 million. The company has developed a computational platform that systematically identifies the transcriptomic and epigenetic switches required to control human cell fate.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2473

Mogrify

Longevity level(s):

  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.
  • Level 8: Systemic aging reversal
    Therapeutic interventions that stop or reverse age-related damage throughout the whole body system at a cellular level. Including technologies such as mitochondrial transplant, senotherapeutics and partial cellular reprogramming.

Overview

Mogrify is a regenerative medicine company developing a novel class of in vivo cellular reprogramming therapies targeting degenerative diseases with high unmet clinical need. The company leverages proprietary computational platforms to identify optimal combinations of transcription factors and growth factors required to convert one cell type into another, enabling direct cellular transdifferentiation. Mogrify's therapeutic pipeline addresses sensorineural hearing loss, retinal degeneration, and Type I diabetes through both ex vivo and in vivo reprogramming approaches. The company combines systematic big-data analysis with next-generation sequencing and epigenetic network data to accelerate the development of functional cell types for regenerative medicine applications.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Beauty giant and supplement startup both chase skin aging

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE